ChemotherapyFDA-approvedAdjuvant
mFOLFOX6
Generic name: oxaliplatin
How it works
Forms platinum-DNA adducts, causing DNA damage and triggering cell death.
Cancer types
Colorectal Cancer— All patients
Efficacy
Clinical trials demonstrate that mFOLFOX6 can improve disease-free survival in patients with stage III colorectal cancer compared to 5-fluorouracil/leucovorin.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing New Treatment for Colorectal Cancer Spreading to the Peritoneum | Colorectal Cancer | phase-1 | — | Source → |
| MYC Protein Linked to Resistance to Cancer Treatment | Colorectal Cancer | lab-study | — | Source → |
| Testing Bevacizumab with Chemotherapy for Metastatic Colorectal Cancer | Colorectal Cancer | phase-3 | — | Source → |
| Testing Chemo-Immunotherapy for Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Testing Lung Perfusion with Oxaliplatin for Colorectal Cancer | Colorectal Cancer | phase-1 | — | Source → |
| Rectal Cancer Trial Examines New Treatment Combination | Colorectal Cancer | phase-2 | — | Source → |
| Evaluating a Combination Treatment for Metastatic Colorectal Cancer in Elderly Patients | Colorectal Cancer | phase-2 | — | Source → |
| Blueberry Anthocyanins Enhance Chemotherapy Effectiveness in Colon Cancer Cells | Colorectal Cancer | lab-study | The combination of blueberry anthocyanins and oxaliplatin significantly inhibited the proliferation and colony formation of HCT116 and LOVO cells (P<0.01) and markedly suppressed tumor growth in the nude mouse xenograft model (P<0.05). | Source → |
| Oxaliplatin Side Effect Study in Colorectal Cancer Patients | Colorectal Cancer | phase-3 | — | Source → |
| New Treatment Shows Promise for Colorectal Cancer Patients | Colorectal Cancer | phase-1 | Compared with standard therapy, PIPAC-Oxaliplatin was associated with higher median good days at 6 months (181 vs 131 days; p = 0.042) and 1 year (323 vs 131 days; p = 0.032), and longer overall survival (median, 11.3 vs 5.1 months; p = 0.036). | Source → |
| Oxaliplatin Chemotherapy Less Effective in Colorectal Cancer with High WTAP Levels | Colorectal Cancer | lab-study | — | Source → |
| GL-V9 Enhances Effectiveness of Colorectal Cancer Treatment | Colorectal Cancer | lab-study | — | Source → |
| Rare Side Effect of Cancer Drug: Transient Ischemic Attack | Colorectal Cancer | observational | — | Source → |
| Combination Therapy Shows Promise Against Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Chemotherapy Side Effect Causes Loss of Consciousness in Cancer Patient | Colorectal Cancer | observational | — | Source → |
| Study Examines Effectiveness of S-1 and Oxaliplatin in Treating Colorectal Liver Metastases | Colorectal Cancer | phase-2 | The disease-free survival (DFS) at 3 years was 52.9% in the low-dose group. | Source → |
| Researchers Identify Potential Biomarkers for Colorectal Cancer Resistance to Oxaliplatin | Colorectal Cancer | lab-study | — | Source → |
| Chemotherapy Sensitizes Colorectal Cancers to Immunotherapy | Colorectal Cancer | lab-study | — | Source → |
| Researchers Explore New Way to Deliver Cancer Drug | Colorectal Cancer | review | — | Source → |
| Comparing Two Chemotherapy Regimens for Rectal Cancer | Colorectal Cancer | phase-3 | The pathological complete response rate was 17.9% vs. 5.1% (P< .001), the 3 year disease-free survival rate was 75% vs. 66.7% (P = .047), and the distant metastasis rate was 16.4% versus 26.6% (P = .013) for mFOLFOXIRI and mFOLFOX6 group, respectively. | Source → |
| Oxaliplatin Resistance in Colorectal Cancer | Colorectal Cancer | lab-study | — | Source → |
| How Two Cancer Drugs Affect Cells Differently | Lung Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.